FDA — authorised 29 October 2019
- Marketing authorisation holder: BIOGEN INC
- Status: approved
🇺🇸 Vumerity in United States
FDA authorised Vumerity on 29 October 2019
Marketing authorisations
FDA — authorised 29 October 2019
- Application: NDA211855
- Marketing authorisation holder: BIOGEN INC
- Indication: Type 2 - New Active Ingredient
- Status: approved
Vumerity in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Vumerity approved in United States?
Yes. FDA authorised it on 29 October 2019; FDA authorised it on 29 October 2019.
Who is the marketing authorisation holder for Vumerity in United States?
BIOGEN INC holds the US marketing authorisation.